Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(0)
•••
fransk89
X
View Profile
View Bullboard History
Post by
fransk89
on Jan 21, 2022 6:14am
HERBAL FORMULA FOR IPF
I suffered deeply with stage four sarcoidosis which progressed to idiopathic pulmonary fibrosis (IPF). I was hospitalized eighteen times in three years, mostly with flare ups and pneumonia. For me
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 20, 2022 11:27am
RE:RE:RE:RE:RE:RE:RE:RE:Streetwise Reports:
Admirable but a moot point once uplisted to Nasdaq. hopefully sooner rather tghan later.
Debt-Free and Thriving: Mining Company Reports 35% Revenue Growth in Q3 2024
posted Nov 12, 2024 9:00am by
Mandalay Resources Corp.
-
|
"Revenue growth and free cash flow generation reflect our cost controls and prudent capital management while benefitting from high metal prices. As of the end of Q3 our cash balance was a healthy $54.7 million – more than doubling since December 2023 – and we have fully repaid the $20 million outstanding balance on our revolving credit facility, strengthening our liquidity and financial flexibility ...read more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 20, 2022 10:35am
RE:RE:RE:RE:RE:RE:RE:Streetwise Reports:
The endangerment of Algernon by price depression, IMO, would be a public harm to honest investors and sick people who would benefit from Algernon's disease remedies. It is the duty and
...more
(3213)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Jan 19, 2022 7:09pm
The Power Play by The Market Herald Releases Interviews
(Sponsored) Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK Medicines and Healthcare Products Regulatory Agency (MHRA
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 19, 2022 4:30pm
RE:RE:RE:RE:RE:RE:Streetwise Reports:
That would have been a good question to ask the CEO at the Q&A yetserday. The buck stops with the CEO IF THEY BELIEVE something nefarious is taking place with stock manipulation. Former Algernon -
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 19, 2022 3:40pm
RE:RE:RE:RE:RE:Streetwise Reports:
Or at least that the price has nothing to do with the company but is whatever day traders want it to be - regardless of value investors or, indeed, stroke patients, So, I repeat my question. Where
...more
(1121)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Jan 19, 2022 1:28pm
RE:RE:RE:RE:Streetwise Reports:
Looks like they're better off when they don't put out news!
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 19, 2022 11:28am
Price Drop
Hee we go again! Good news from the UK and the share price plummets - and Integral Wealth Securities is, again, in the thick of it. Where the hell are the regulators?
(792)
•••
Parker5295
X
View Profile
View Bullboard History
Post by
Parker5295
on Jan 19, 2022 7:46am
Files for Trial & Ethics Approval for DMT Human Stroke Study
https://www.globenewswire.com/en/news-release/2022/01/19/2369181/0/en/Algernon-Pharmaceuticals-Files-for-Clinical-Trial-and-Ethics-Approval-for-Phase-1-DMT-Human-Stroke-Study.html Algernon
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 18, 2022 9:37pm
RE:RE:RE:Streetwise Reports:
As Far As The Eye Can See
(1121)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Jan 18, 2022 10:13am
RE:RE:Streetwise Reports:
So we're now back to 12 cents How far do you see it going.
(334)
•••
Goldhog
X
View Profile
View Bullboard History
Post by
Goldhog
on Jan 18, 2022 10:10am
11.80 nice
93% to go
(334)
•••
Goldhog
X
View Profile
View Bullboard History
Comment by
Goldhog
on Jan 18, 2022 1:27am
RE:RE:RE:RE:RE:Price Drop
Same. Thanks
(3)
•••
fruiscante1
X
View Profile
View Bullboard History
Comment by
fruiscante1
on Jan 18, 2022 12:37am
RE:RE:RE:RE:Price Drop
Can anyone who saw it please provide a summary or any key takeaways? Thanks!
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 17, 2022 9:07pm
RE:Streetwise Reports:
Those numbers by PennyQueen at Streetwise Capital, as good as they may seem are actually low ball numbers if you use the actual valuation method by Bay Bridge Bio. Two Phase 1 clinical
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Meet the Top 5 Best Online Brokerages in Canada
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Star Diamond Corporation Announces Third Quarter 2024 Results
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.